Physician profile
Ehtesham Khalid
NPI 1528493202
$82,110.00
in general payments reported to CMS, 2019-2025
14 companies · $58K in 2025
The $58K reported for 2025 was more than what 95% of Neuromuscular Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $7,368 · 2024: $17K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $58K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $4,479 · Food and Beverage: $3,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $57,938.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,208.00 |
| Travel and Lodging | $4,479.32 |
| Food and Beverage | $3,484.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $23,837.92 | 2023-2025 | Ultomiris |
| Genzyme Corporation | $21,443.27 | 2023-2025 | |
| Janssen Biotech, INC. | $12,147.14 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $9,696.24 | 2024 | Hyqvia |
| Ucb, INC. | $8,143.63 | 2024-2025 | Rystiggo, Zilbrysq |
| Amgen INC. | $3,194.12 | 2024 | Uplizna |
| Astrazeneca Pharmaceuticals Lp | $2,469.00 | 2025 | Wainua |
| Argenx US, INC. | $651.01 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Alnylam Pharmaceuticals INC. | $157.28 | 2023-2024 | Amvuttra, Onpattro |
| Grifols USA, LLC | $150.49 | 2023 | Gamunex-C |
| Amylyx Pharmaceuticals, INC. | $123.74 | 2023 | Relyvrio |
| Tanabe Pharma America, INC. | $73.26 | 2024-2025 | Radicava |
| Averitas Pharma INC. | $22.90 | 2024 | Qutenza |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ehtesham Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.